

This article was originally published [here](#)

The APR-246, azacitidine combination has been granted breakthrough therapy status for the treatment of myelodysplastic syndromes in patients having a susceptible TP53 mutation. Myelodysplastic syndromes are defined as

The post [Aprea Therapeutics gets FDA breakthrough therapy status for APR-246 in MDS](#) appeared first on [Pharmaceutical Business review](#).